- Increased demand for diabetes testing is a challenge for clinical laboratories.
- The Atellica® CH Enzymatic Hemoglobin A1c (A1c_E) Assay1 is an easy-to-implement chemistry test, offering precise and accurate results for diabetic patient management.2
- The A1c_E assay is less prone to testing interference3 and greatly improves HbA1c testing throughput compared to traditional HPLC assays.
Siemens Healthineers announced today the global availability of its new Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians in diagnosing and monitoring diabetes, a growing and potentially deadly disease.
The International Diabetes Federation projects 642 million people worldwide will have diabetes by 2040 because of leading factors such as higher levels of urbanization, aging populations, and the growing adoption of more sedentary lifestyles which leads to insufficient physical activity, greater rates of obesity and a higher intake of unhealthy foods.4 When diagnosed, treated and monitored regularly, diabetes is manageable and, in some cases, reversible. Left untreated, however, blood sugar can rise to dangerous levels and lead to kidney damage and other irreversible health consequences.
As diabetes awareness increases and screening for the chronic disease rises, testing options for the clinical laboratory are evolving both in sophistication and practicality. The Siemens Healthineers Atellica CH Enzymatic Hemoglobin A1c meets new standards of testing and offers laboratories improved performance—both precision and accuracy2—over leading alternative methodologies.
“Demands for screening and monitoring on the laboratory will continue to grow as the diabetic population continues to expand,” said Deepak Nath, PhD, President of Laboratory Diagnostics, Siemens Healthineers. “Instruments with higher throughput capabilities offer laboratories the ability to run a greater volume of tests and produce patient results more quickly, thus improving patient satisfaction. Laboratories are seeking HbA1c assays that can be integrated onto chemistry testing platforms and that provide the accurate and precise results patients deserve. The new Atellica CH Enzymatic Hemoglobin A1c Assay offers these capabilities.”
Siemens Healthineers offers a variety of HbA1c assays for diabetes testing on its clinical laboratory and point-of-care solutions, including the Atellica® CH Analyzer, ADVIA® Chemistry Systems, Dimension® Systems, Dimension Vista® Systems, and the DCA Vantage® Analyzer.
For further information on the Atellica CH A1c_E Assay, please see: http://siemens-healthineers.com/atellica-hba1c
1 Product availability varies by country.
2 Atellica CH A1c_E IFU. Siemens Healthcare Diagnostics Inc. 11111609_EN Rev. 01, 2019-01
3 The Atellica CH A1c_E assay is NGSP certified and an IFCC-standardized HbA1c assay that demonstrates < 5% change with most known Hb variants (HbC, HbD, HbE, HbS, and HbA2).
4 International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.